Indeed, hematopoietic stem/progenitor cells from patients with ASXL1-mutated AML have a higher expression of BCL2 [94], and relapsed–refractory ASXL1-mutated AML treated with HMA and VEN had improved CR/CRi rates in a retrospective study [92]. The gene discussed is ASXL1; the disease is acute myeloid leukemia.